Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3175

Sort by

Sort Order Select

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, PharmD, PhD, Juliette Soret-Dulphy, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Pierre-Emmanuel Rautou, MD PhD, Aurelie Plessier, Dominique Valla, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 836.

https://doi.org/10.1182/blood-2019-123775

Published: 2019

Journal Articles

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Leonard Naymagon, MD, Douglas Tremblay, MD, Nicole Zubizarreta, MPH, Erin Moshier, MS, Thomas Schiano, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1154.

https://doi.org/10.1182/blood-2019-124042

Published: 2019

Journal Articles

Outcomes in Older Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Linker Protocol at a Single Center Institution

Cindy Lynn Hickey, MDFRCPC, David Conrad, MD PhD, Stephen Couban, MDBSc

Blood (2019) 134 (Supplement_1): 1308.

https://doi.org/10.1182/blood-2019-121336

Published: 2019

Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Blood (2019) 134 (Supplement_1): 845.

https://doi.org/10.1182/blood-2019-122802

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Blood (2019) 134 (Supplement_1): 1710.

https://doi.org/10.1182/blood-2019-123877

Published: 2019

Journal Articles

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Akihiko Sawaki, MD, Kana Miyazaki, MD PhD, Toshifumi Takeuchi, MD PhD, Kyoko Kobayashi, MD PhD, Hiroshi Imai, MD PhD, Isao Tawara, MD PhD, Ryoichi Ono, MD PhD, Tetsuya Nosaka, MD PhD, Motoko Yamaguchi, MD PhD, Naoyuki Katayama, MD PhD

Blood (2019) 134 (Supplement_1): 1624.

https://doi.org/10.1182/blood-2019-122796

Published: 2019

Journal Articles

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Giovanni Del Poeta, MD, Annalisa Biagi, MD, Annalisa Chiarenza, MD PhD, Luca Laurenti, MD, Federico Pozzo, MSc, Idanna Innocenti, MD PhD, Riccardo Bomben, PhD, Maria Ilaria Del Principe, Enrico Santinelli, MD, Francesca Maria Rossi, PhD, Paolo de Fabritiis, MD, Maria Cantonetti, Antonella Zucchetto, William Arcese, Valter Gattei, MD

Blood (2019) 134 (Supplement_1): 1744.

https://doi.org/10.1182/blood-2019-122481

Published: 2019

Journal Articles

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Alessandra Carobbio, BSc, Elisa Rumi, MD, Valerio De Stefano, MD, Lara Mannelli, MD, Francesco Mannelli, MD, Giada Rotunno, PhD, Giacomo Coltro, MD, Silvia Betti, MD PhD, Chiara Cavalloni, MD, Maria Chiara Finazzi, MD, Juergen Thiele, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 1657.

https://doi.org/10.1182/blood-2019-124302

Published: 2019

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Anthony M. Hunter, MD, Najla Al Ali, M.Sc, David A Sallman, MD, Kendra L. Sweet, MD, Andrew T Kuykendall, MD, Chetasi Talati, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 1717.

https://doi.org/10.1182/blood-2019-131071

Published: 2019

Journal Articles

Pegylated Interferon-Alfa Suppresses Clonal Hematopoiesis in Polycythemia Vera and Essential Thrombocythemia and Is Associated with Immune Responses to Tumor Antigens

Tsewang Tashi, MD, Tim Luetkens, MD, Stephanie Avila, Soo Jin Kim, MS, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 1691.

https://doi.org/10.1182/blood-2019-131974

Published: 2019

Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD

Blood (2019) 134 (Supplement_1): 1718.

https://doi.org/10.1182/blood-2019-129129

Published: 2019

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Sabina Kersting, MD PhD, Mark-David Levin, MD PhD, Carsten Utoft Niemann, MD PhD, Yvette Norden, PhD, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 1753.

https://doi.org/10.1182/blood-2019-124550

Published: 2019

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

NARROW

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Outcomes in Older Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Linker Protocol at a Single Center Institution

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA)

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Pegylated Interferon-Alfa Suppresses Clonal Hematopoiesis in Polycythemia Vera and Essential Thrombocythemia and Is Associated with Immune Responses to Tumor Antigens

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only